Glovista Investments’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Glovista Investments’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-21,135	Closed	-$2.87M	–	120
2021 Q2	$2.87M	Buy	+21,135	New	+$2.78M	0.68%	31
2020 Q3	–	Sell	-20,830	Closed	-$2.33M	–	102
2020 Q2	$2.33M	Buy	+20,830	New	+$2.05M	0.91%	28
2018 Q1	–	Sell	-5,823	Closed	-$494K	–	101
2017 Q4	$494K	Sell	5,823 -117,973	-95%	-$9.88M	0.1%	68
2017 Q3	$10.7M	Buy	123,796 +119,420	+2,729%	+$9.57M	2.05%	14
2017 Q2	$3.38M	Buy	+4,376	New	+$310K	0.74%	28

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Glovista Investments's XBI Position: Q3 2021 in Review

Glovista Investments sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2021, closing a stake of 21,135 shares — an estimated $2.87M sold.

Glovista Investments first reported a position in XBI in Q2 2017 and held it in 5 quarters. The position peaked at $10.7M in Q3 2017. 635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.

Glovista Investments reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2021 after selling out during the quarter.
Glovista Investments sold 21,135 State Street SPDR S&P Biotech ETF shares in Q3 2021, an estimated $2.87M.
Glovista Investments first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and held it in 5 quarters.
Glovista Investments's State Street SPDR S&P Biotech ETF position peaked at $10.7M in Q3 2017.
635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.

Based on Glovista Investments's 13F filing for Q3 2021, filed 12 Nov 2021.